Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 26Neuroblastoma 25Breast Neoplasms 20Prostatic Neoplasms 18Leukemia 15Multiple Myeloma 14Lymphoma 14Leukemia, Myeloid, Acute 14Glioblastoma 14Lymphoma, Non-Hodgkin 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Leukemia, Lymphocytic, Chronic, B-Cell 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms, Male 8Myelodysplastic Syndromes 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Glioma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Fallopian Tube Neoplasms 6Osteosarcoma 5Hodgkin Disease 5Carcinoma, Renal Cell 5Brain Neoplasms 5Uveal Melanoma 4Recurrence 4Rectal Neoplasms 4Medulloblastoma 4

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 1 Completed
83 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡